San Diego-based Illumina Inc. (Nasdaq: ILMN) and Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE: WX) have announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.
This new investment will enable WuXi's clinical genomic services to expand from the current target panel, exome and transcriptome scale sequencing to population genome scale sequencing. It puts the world's most advanced gene sequencing capability in the hands of the leading pharmaceutical research and development services company in the Asia Pacific region.
WuXi PharmaTech is a pharmaceutical, biotechnology and medical device research and development outsourcing company.
The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi's genomics lab also provides assay development, validation, and testing services.
“This investment in cutting-edge gene sequencing technology significantly strengthens WuXi's broad, integrated platform of R&D services,” said Dr. Ge Li, chairman and CEO of WuXi PharmaTech, in a statement. “It advances our mission of enabling anyone and any company to use our R&D platform to discover and develop innovative medicines to benefit the world's patients.”
The HiSeq X Ten is the world's first platform to deliver full coverage human genomes for $1,000 including typical instrument depreciation, DNA extraction, library preparation and estimated labor.
9885 Towne Centre Dr.
San Diego, CA 92121